| AGEN |
Agenus Inc. |
90%
|
Reciprocal relationship from AGEN graph: Reciprocal relationship from LGND graph: Reciprocal relationship from AGEN graph: The Amendment Agreement provides for a release by Ligand of liens it has on … |
| CAPVAXIVE |
CAPVAXIVE |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| FILSPARI |
FILSPARI |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| KYPROLIS |
KYPROLIS |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| OHTUVAYRE |
OHTUVAYRE |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| PARTNERS |
PARTNERS |
90%
|
We rely on our partners' earning releases and other information from our partners to determine the sales of our partners' products and to estimate the related royalty revenues. |
| RYLAZE |
RYLAZE |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| TERIPARATIDE-INJECTION |
TERIPARATIDE-INJECTION |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| VAXNEUVANCE |
VAXNEUVANCE |
90%
|
Revenue from intangible royalty assets is a function of our partners’ product sales and the applicable royalty rate. |
| VKTX |
Viking Therapeutics, Inc. |
90%
|
Reciprocal relationship from VKTX graph: Reciprocal relationship from LGND graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will f… |
| LONA |
LeonaBio, Inc. |
80%
|
Reciprocal relationship from LONA graph: granting the Company exclusive licenses and rights to develop, manufacture and commercialize oral forms of the selective estrogen-receptor modulator known as … |
| XI-AN-XINTONG |
XI-AN-XINTONG |
80%
|
Contract revenue and income decreased by $4.3 million, or (97)%, to $0.1 million in Q1 2026 compared to $4.4 million in Q1 2025, primarily due to a regulatory milestone tied to Xi’an Xintong’s Xinshu… |
| DNTH |
Dianthus Therapeutics, Inc. |
72%
|
Reciprocal relationship from DNTH graph: Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2… |
| LLY |
Eli Lilly and Company |
72%
|
entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or … |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LLY graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LLY grap… |
| OVID |
Ovid Therapeutics Inc. |
72%
|
tia”) in September 2023) in 2017, Ovid Therapeutics Inc. (“Ovid”) in October 2023, Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) in November 2023, and from certain ensifentrine inventors in… |
| OVID |
Ovid Therapeutics Inc. |
72%
|
Reciprocal relationship from OVID graph: Reciprocal relationship from LGND graph: tia”) in September 2023) in 2017, Ovid Therapeutics Inc. (“Ovid”) in October 2023, Tolerance Therapeutics, Inc. (“Tol… |
| PVLA |
Palvella Therapeutics, Inc. |
72%
|
Reciprocal relationship from PVLA graph: Reciprocal relationship from LGND graph: ,115 23,401 22,262 Less accumulated depreciation and amortization ( 8,268 ) ( 6,655 ) $ 15,133 $ 15,607 Depreciation … |
| PVLA |
Palvella Therapeutics, Inc. |
72%
|
,115 23,401 22,262 Less accumulated depreciation and amortization ( 8,268 ) ( 6,655 ) $ 15,133 $ 15,607 Depreciation of equipment is computed using the straight-line method over the estimated useful … |
| SNYNF |
Sanofi |
72%
|
entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGND graph: entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will … |
| APEIRON-BIOLOGICS-AG |
APEIRON-BIOLOGICS-AG |
62%
|
ing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical com… |
| ARECOR-LIMITED |
ARECOR-LIMITED |
62%
|
stock price of $ 21.01 and $ 31.00 . We recognized a mark-to-market adjustment of $( 2.0 ) million for the three months ended March 31, 2026. We accounted for the convertible note as a receivable und… |
| BIOLOGICS-AG |
BIOLOGICS-AG |
62%
|
as of May 29, 2024. For additional information on the Agenus BOT/BAL rights, see “Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)”. 3. Acquisitions Apeiron On Ju… |
| CASTLE-CREEK-BIOSCIENCES-INC |
CASTLE-CREEK-BIOSCIENCES-INC |
62%
|
ing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical com… |
| CASTLE-CREEK-BIOSCIENCES-INC-CASTLE-CREEK-BIOSCI |
CASTLE-CREEK-BIOSCIENCES-INC-CASTLE-CREEK-BIOSCI |
62%
|
estra Warrant”). The transaction closed on August 4, 2025. The $ 5.0 million equity private placement is included in our short-term investments and is subsequently measured at fair value at each repo… |
| INVIOS-HOLDING-AG |
INVIOS-HOLDING-AG |
62%
|
tory approval and commercialization in the USA. We evaluated this acquisition in accordance with ASC 805, Business Combinations , to discern whether the assets and operations of Apeiron met the defin… |
| PELICAN-TECHNOLOGY-HOLDINGS-INC |
PELICAN-TECHNOLOGY-HOLDINGS-INC |
62%
|
r value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value. Novan On September 27, 2023, we closed the transaction to acquire cer… |
| PIERIS-PHARMACEUTICALS-INC |
PIERIS-PHARMACEUTICALS-INC |
62%
|
,115 23,401 22,262 Less accumulated depreciation and amortization ( 8,268 ) ( 6,655 ) $ 15,133 $ 15,607 Depreciation of equipment is computed using the straight-line method over the estimated useful … |
| PROVENTION-BIO-INC |
PROVENTION-BIO-INC |
62%
|
entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or … |
